MTOR and ovarian cancer: Given that the PI3K/AKT/mTOR pathway is frequently activated in ovarian cancer and obesity, this study aimed to access the anti-tumorigenic efficacy of everolimus in ovarian cancer cells under different glucose conditions in vitro and in lean and obese mouse models of serous ovarian cancer in vivo.